@BreastCaConnect

COR2ED brings you Independent Medical Education developed by BREAST CANCER CONNECT, experts in Breast Cancer. https://nitter.cf/t.co/loqcKrHH5M

cor2ed.com
Joined February 2023
  • Tweets515
  • Following359
  • Followers2.4K
280Media
Pre-analytical phase challenges & biomarker testing in HER2+ metastatic breast cancer From Prof. Gary Tse, Dr Carlos Barrios, & @OncBrothers Highlights in this video 📹 Watch full video or listen on Spotify/Apple: cor2ed.com/precision-oncolog… >> Endorsed by @BiomarkerCo Supported by an Independent Educational Grant from Daiichi Sankyo. For HCPs only. #MedEd #BCSM #PrecisionMedicine
1
222
ADCs in HER2+ metastatic breast cancer: management of adverse events Downloadable BluePrint to use in your clinical practice! Get clear, practical strategies for managing TRAEs: N/V, fatigue, ILD From Dr @stolaney1, Prof. @Shaheenah1, Prof. @JavierCortesMD, @CarlaWhitbread, Dr Grazyna Suchodolska, & Prof. Giuseppe Curigliano Download the BluePrint & watch the expert videos 📺 for further insights: cor2ed.com/breast-cancer-con… 🤝 Endorsed by the European Oncology Nursing Society (@cancernurseEU) and @EuropaDonnaEUR Supported by an Independent Educational Grant from AstraZeneca. For HCPs only. #MedEd #MedTwitter #BCSM
1
1
3
2,246
ADCs in HER2+ metastatic breast cancer: management of adverse events 🔸 T-DXd is highly emetogenic 🔸 Breakthrough N/V may occur despite prophylaxis, requiring appropriate management 🔸 Fatigue associated w/ T-DXd should be proactively managed 🔸 ILD is a potentially serious AE w/ T-DXd; early detection is critical Get step-by-step guidance on best practice Downloadable BluePrint for HCPs & patients ⬇️ cor2ed.com/breast-cancer-con… From Dr @stolaney1, Prof. @Shaheenah1, Prof. @JavierCortesMD, @CarlaWhitbread, Dr Grazyna Suchodolska, & Prof. Giuseppe Curigliano 🤝 Endorsed by the European Oncology Nursing Society (@cancernurseEU) and @EuropaDonnaEUR Supported by an Independent Educational Grant from AstraZeneca #MedEd #MedTwitter #BCSM 📺
4
814
Pre-analytical phase challenges & biomarker testing in HER2+ metastatic breast cancer From Prof. Gary Tse, Dr Carlos Barrios, & @OncBrothers Highlights in this video 📹 >> Endorsed by @BiomarkerCo Supported by an Independent Educational Grant from Daiichi Sankyo. For HCPs only.
131
181
4
3,003
20,493,927
Metastatic #BreastCancer: videp podcast 📹 Watch the full video/listen on Spotify or Apple: cor2ed.com/breast-cancer-con… ➡️DESTINY-Breast04 and DESTINY-Breast-06 established T-DXd as an effective option for #HER2-low and HER2-ultralow mBC, improving PFS and OS, and showing that even minimal HER2 expression can identify patients who benefit from T-DXd So how can we correctly identify pts with HER2-low/-ultralow mBC? Explore this topic with resources from medical oncologists @OncBrothers & Dr @jhaveri_komal 🗣️ Conversation highlights in this post Supported by an Independent Educational Grant from AstraZeneca #MedEd #BCSM #OncTwitter #MedTwitter
3
955
ADCs in HER2+ metastatic breast cancer: management of adverse events Get step-by-step strategies to support effective management of T-DXd–related adverse events in HER2+ mBC ✔️ N/V ✔️ Fatigue ✔️ Interstitial lung disease (rare but critical) Downloadable BluePrint for HCPs & patients From Dr @stolaney1, Prof. @Shaheenah1, Prof. @JavierCortesMD, @CarlaWhitbread, Dr Grazyna Suchodolska, & Prof. Giuseppe Curigliano cor2ed.com/breast-cancer-con… 🤝 Endorsed by the European Oncology Nursing Society (@cancernurseEU) and @EuropaDonnaEUR Supported by an Independent Educational Grant from AstraZeneca #MedEd #MedTwitter #BCSM 📺
389
📺 @CarlaWhitbread shares a patient‑focused perspective on adverse events from ADCs in HER2+ metastatic breast cancer 🔸Get clear, practical approaches to recognising and managing T-DXd-related AEs, like N/V, fatigue & ILD 🔸Download the BluePrint, featuring a 1-page factsheet to share with your pts to help them understand what to look out for and how to seek help cor2ed.com/breast-cancer-con… 🤝 Endorsed by the European Oncology Nursing Society (@cancernurseEU) and @EuropaDonnaEUR Supported by an Independent Educational Grant from AstraZeneca #MedEd #MedTwitter #BCSM
1
286
DESTINY-Breast04 & DESTINY-Breast06 demonstrated that T-DXd provides clinically meaningful benefit in pts w/ HER2-low/-ultralow #breastcancer ✔️ HER2 assessment has shifted from a binary classification to a therapeutic continuum ✔️ Accurate HER2 scoring & recognition of its dynamic nature are now essential to identify eligible patients & optimise treatment decisions Experts @OncBrothers & Dr @jhaveri_komal discuss this topic Conversation highlights in this post 📹 Watch the full video or listen on Spotify/Apple: cor2ed.com/breast-cancer-con… Supported by an Independent Educational Grant from AstraZeneca #MedEd #OncTwitter #BCSM #MedTwitter
1
269
BREAST CANCER CONNECT powered by COR2ED retweeted
COR2ED
@COR2EDMedEdJun 10
📣 Update from #ASCO26! Renowned experts share their views on new data emerging from the @ASCO Annual Meeting 👉 𝘏𝘌𝘙2-mutant NSCLC: Dr @herbloong & Dr @ipreeshagul data from SOHO-01, PRO data from Beamion LUNG-1, and more ~Endorsed by @WarOnCancer, @BiomarkerCo, @Exon20Group & @isliquidbiopsy (📺Video in this post! Slides also available: cor2ed.com/n-connect/program…) 👉 #NSCLC: Prof. @MarkSocinski reviews #LungCancer data from #LIBRETTO-432, WU-KONG28 & #HARMONi-6 ~Endorsed by International Cancer Advocacy Network, Biomarker Collaborative, Exon20 Group & International Society of Liquid Biopsy 👉 #ProstateCancer: Prof. Evan Yu reviews data from #PROTEUS & #TALAPRO-3 ~Endorsed by International Cancer Advocacy Network 👉 #ColorectalCancer, #PancreaticCancer & #LiverCancer: Prof. @HPrenen reviews data from #RASolute 302, #BREAKWATER & #EMERALD-3 ~Endorsed by International Cancer Advocacy Network & @dice_europe 👉 #BreastCancer: Dr @PtarantinoMD reviews data from #ASCENT-03, ASCENT-04, #TROPION-Breast02, #SERENA-6, #VIKTORIA-1, & #OPTIMA ~Endorsed by International Cancer Advocacy Network How will these data impact clinical practice? Watch the videos to find out! ▶️ cor2ed.com/n-connect/program… 𝘏𝘌𝘙2-mutant NSCLC update supported by an Independent Educational Grant from Bayer. All other updates supported by COR2ED. #MedEd #OncTwitter #MedTwitter #Oncology
8
12
857
🔬 #PrecisionOncology in HER2+ metastatic #breastcancer ❓ What challenges do we face at the pre-analytical phase? ❓ How can we address these challenges to optimise outcomes? Expert discussion from Prof. Gary Tse, Dr Carlos Barrios, & @OncBrothers 📹 Watch the full video 🎙️ Listen on Spotify/Apple cor2ed.com/precision-oncolog… 🤝 Endorsed by @BiomarkerCo Supported by an Independent Educational Grant from Daiichi Sankyo. For HCPs only. #MedEd #BCSM #PrecisionMedicine
1
1
3
514
BREAST CANCER CONNECT powered by COR2ED retweeted
PRECISION ONCOLOGY CONNECT powered by COR2ED
@PresOnc_ConnectMay 26
Could better HER2 classification mean more patients accessing targeted treatment options? Prof. Gary Tse and Dr Carlos Barrios discuss the importance of accurate biomarker testing and reducing missed opportunities in mBC. #MedEd
PRECISION ONCOLOGY CONNECT powered by COR2ED
@PresOnc_ConnectMay 12
Pre-analytical phase challenges & biomarker testing in HER2+ metastatic breast cancer From Prof. Gary Tse, Dr Carlos Barrios, & @OncBrothers Highlights in this video 📹 Watch full video or listen on Spotify/Apple: cor2ed.com/precision-oncolog… >> Endorsed by @BiomarkerCo Supported by an Independent Educational Grant from Daiichi Sankyo. For HCPs only. #MedEd #BCSM #PrecisionMedicine
3
7
426
BREAST CANCER CONNECT powered by COR2ED retweeted
OncoAlert
@OncoAlertJun 4
Get expert insights on the latest data in lung, prostate, GI, and breast cancers presented at #ASCO26 . Renowned medical experts join @COR2EDMedEd in Chicago to share their views on data emerging from the meeting. How will new trial data impact clinical practice? Watch the video updates to find out! buff.ly/eQiz2b7 @herbloong @ipreeshagul @PTarantinoMD
15
17
1,994
BREAST CANCER CONNECT powered by COR2ED retweeted
OncoAlert
@OncoAlertJun 5
Lung cancer 🫁 update from #ASCO26 👉 buff.ly/9P3rYdv Renowned lung cancer experts join our collaborators at COR2ED at ASCO 2026 to discuss breaking data emerging from the meeting. Watch the video updates for insights on HER2-mutant non-small cell lung cancer (NSCLC) from Drs Herbert Loong and Isabel Preeshagul, and analysis of other key lung cancer trial data from Prof. Mark Socinski. #LungCancer #NSCLC #SCLC @herbloong @ipreeshagul
16
2
19
2,575
BREAST CANCER CONNECT powered by COR2ED retweeted
BREAST CANCER CONNECT powered by COR2ED
@BreastCaConnectJun 3
📣#BreastCancer highlights from #ASCO26! Dr @PtarantinoMD shares his expert insights on key #trialdata from #ASCENT-03, ASCENT-04, #TROPION-Breast02, #SERENA-6, #VIKTORIA-1, & #OPTIMA How will these data impact clinical practice? Watch his update to find out! 🤝 Programme endorsed by @WarOnCancer 📺See more updates from @ASCO in 𝘏𝘌𝘙2-mutant #NSCLC, #LungCancer, #GIcancer & #ProstateCancer ⬇️ cor2ed.com/n-connect/program… This educational programme is supported by COR2ED #MedEd #BCSM
6
1
9
8,135
BREAST CANCER CONNECT powered by COR2ED retweeted
OncoAlert
@OncoAlertJun 4
GI and hepatobiliary cancer update from ASCO 2026 Medical oncologist Prof. Hans Prenen joins @COR2EDMedEd in Chicago to share his expert insights on the latest data in colorectal, pancreatic, and liver cancers presented at ASCO 2026. How will late-breaking data impact clinical practice? Watch his video update to find out. buff.ly/dSEZYZp
14
17
1,539
HER2 expression can change over time and between tumour sites. The @OncBrothers and @jhaveri_komal discuss HER2-low and HER2-ultralow classification, including when re-biopsy may help identify patients eligible for HER2-targeted therapies. #MedEd
BREAST CANCER CONNECT powered by COR2ED
@BreastCaConnectMay 31
Understanding HER2-low and HER2-ultralow classification in metastatic breast cancer >> A novel therapeutic framework 📹 From @OncBrothers & Dr @jhaveri_komal Explore key trial data, 2025 CAP reporting template, when/why to perform biopsy, best practice in monitoring AEs & more! Watch the full video! ⤵️ cor2ed.com/breast-cancer-con… Supported by an Independent Educational Grant from AstraZeneca #MedEd #BreastCancer #MedTwitter
174
BREAST CANCER CONNECT powered by COR2ED retweeted
OncoAlert
@OncoAlertJun 3
Breast Cancer Update from ASCO 2026 : Watch Dr @PTarantinoMD joins @COR2EDMedEd in Chicago to share his views on the latest breast cancer data emerging from ASCO 2026. How will new developments impact clinical practice? Watch his update to find out! buff.ly/iLLs16U
1
17
19
1,528
📣#BreastCancer highlights from #ASCO26! Dr @PtarantinoMD shares his expert insights on key #trialdata from #ASCENT-03, ASCENT-04, #TROPION-Breast02, #SERENA-6, #VIKTORIA-1, & #OPTIMA How will these data impact clinical practice? Watch his update to find out! 🤝 Programme endorsed by @WarOnCancer 📺See more updates from @ASCO in 𝘏𝘌𝘙2-mutant #NSCLC, #LungCancer, #GIcancer & #ProstateCancer ⬇️ cor2ed.com/n-connect/program… This educational programme is supported by COR2ED #MedEd #BCSM
6
1
9
8,135
BREAST CANCER CONNECT powered by COR2ED retweeted
OncoAlert
@OncoAlertJun 2
Dear Colleagues at #ASCO26 Get expert insights on new #ProstateCancer data emerging from ASCO 2026. Prof. Evan Yu joins @COR2EDMedEd live in Chicago to share his views on how new trial data presented at the meeting could impact the clinical management of patients with prostate cancer. Watch his conference update now. Watch here👉 cor2ed.com/asco-2026/prostat…
13
15
781
BREAST CANCER CONNECT powered by COR2ED retweeted
OncoAlert
@OncoAlertJun 1
Lung cancer 🫁 update from #ASCO26 👉 buff.ly/aQLvoj5 Renowned lung cancer experts join our collaborators at @COR2EDMedEd at ASCO 2026 to discuss breaking data emerging from the meeting. Watch the video updates for insights on HER2-mutant non-small cell lung cancer (NSCLC) from Drs Herbert Loong and Isabel Preeshagul, and analysis of other key lung cancer trial data from Prof. Mark Socinski. #LungCancer #NSCLC #SCLC @herbloong @ipreeshagul
13
1
17
3,135
Load more